Puchner Antonia, Gröchenig Hans Peter, Sautner Judith, Helmy-Bader Yvonne, Juch Herbert, Reinisch Sieglinde, Högenauer Christoph, Koch Robert, Hermann Josef, Studnicka-Benke Andrea, Weger Wolfgang, Puchner Rudolf, Dejaco Clemens
Division of Rheumatology, Third Medical Department, Medical University of Vienna/Vienna General Hospital, Vienna, Austria.
Medical Department, Hospital of the Brothers of Mercy, St. Veit an der Glan, Austria.
Wien Klin Wochenschr. 2019 Jan;131(1-2):29-44. doi: 10.1007/s00508-019-1448-y. Epub 2019 Jan 14.
An increasing and early-onset use of immunosuppressives and biologics has become more frequently seen among patients with inflammatory bowel diseases (IBD) and rheumatic disorders. Many women in their childbearing years currently receive such medications, and some of them in an interdisciplinary setting. Many questions arise in women already pregnant or wishing to conceive with respect to continuing or discontinuing treatment, the risks borne by the newborns and their mothers and long-term safety. Together with the Austrian Society of Rheumatology and Rehabilitation, the IBD working group of the Austrian Society of Gastroenterology and Hepatology has elaborated consensus statements on the use of immunosuppressives and biologics in pregnancy and lactation. This is the first Austrian interdisciplinary consensus on this topic. It is intended to serve as a basis and support for providing advice to our patients and their treating physicians.
免疫抑制剂和生物制剂使用的增加及早期使用在炎症性肠病（IBD）和风湿性疾病患者中越来越常见。许多育龄妇女目前正在接受此类药物治疗，其中一些是在跨学科环境中。对于已经怀孕或希望怀孕的妇女来说，在继续或停止治疗、新生儿及其母亲所承担的风险以及长期安全性方面出现了许多问题。奥地利胃肠病学和肝病学会的IBD工作组与奥地利风湿病学和康复学会共同制定了关于免疫抑制剂和生物制剂在妊娠和哺乳期使用的共识声明。这是奥地利在该主题上的首个跨学科共识。它旨在为向我们的患者及其治疗医生提供建议提供依据和支持。
